ICIs, which target pathways such as the Programmed Cell Death Protein 1 (PD-1) or its ligand (PD-L1) and Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4), have revolutionized the treatment of metastatic NSCLC. This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.